Cerence (CRNC) delivered better-than-expected Fiscal Q1 2022 results characterized by the second-largest bookings quarter in its history. Revenue and earnings topped consensus estimates, but the company lowered its full-year guidance. CRNC shares fell 31.41% to close at $43.61 on February 7.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Cerence develops automotive cognitive assistance solutions to enhance interactions between automobiles and drivers. It also deals in software licenses and cloud-connected services.
Cerence Earnings
Revenue in the quarter landed at $94.4 million, better than the $93.6 million delivered the same quarter last year and higher than the consensus estimate of $94.38 million. Diluted earnings per share in the quarter came in at $0.59, better than analyst estimates of $0.51 and higher than the $0.57 delivered the same quarter last year.
For the fiscal quarter ending March 31, 2022, Cerence is projecting revenue in the range of $82 million to $86 million. Adjusted EBITDA is expected to range between $22 million and $26 million. Full-year revenue is expected at between $365 million and $385 million, a 9% decrease at the midpoint compared to previous guidance. Adjusted EBITDA is expected to range from $119 million to $139 million.
Stock Rating
Last month RBC Capital analyst Joseph Spak downgraded Cerence stock to a Hold from a Buy and cut the price target to $77 from $95, implying 76.57% upside potential to current levels.
Consensus among analysts is a Strong Buy based on 8 Buys and 1 Hold. The average Cerence price target of $110.33 implies 152.99% upside potential to current levels.
Download the TipRanks mobile app now
To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Read full Disclaimer & Disclosure.
Related News:
Google Sued for $2.4B by PriceRunner
Bionano: OGM System on Track for Further Adoption
Why Xpeng’s Business Model Makes it Stand Out